On this basis, epigenetic therapy may be a suitable approach to reawaken PRKN dual tumor suppression in the clinic (30), reinvigorating effector T cell functions in the microenvironment (this study) and tumor antigen presentation (44), while concomitantly inhibiting tumor cell metabolism and invasion (30, 34, 66, 67). The gene discussed is PRKN; the disease is neoplasm.